medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2022-010medsovet-7275Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYЭффективность семаглутида в свете доказательной медициныEfficacy of semaglutide: an evidence-based reviewhttps://orcid.org/0000-0003-1316-5245МкртумянА. М.MkrtumyanA. M.

Мкртумян Ашот Мусаелович, заслуженный врач РФ, д.м.н., профессор, врач-эндокринолог, заведующий кафедрой эндокринологии и диабетологии лечебного факультета; руководитель отдела эндокринных и метаболических нарушений 

127473, Москва, ул. Делегатская, д. 20, стр. 1;111123, Москва, шоссе Энтузиастов, д. 86

Ashot M. Mkrtumyan, Honored Doctor of Russia, Dr. Sci. (Med.), Professor, Endocrinologist, Head of the Department of Endocrinology and Diabetology of the Medical Faculty; Head of the Department of Endocrine and Metabolic Disorders 

20, Bldg. 1, Delegatskaya St., Moscow, 127473;86, Entuziastov Shosse, Moscow, 111123

vagrashot@mail.ruhttps://orcid.org/0000-0001-8817-1901ЕгшатянЛ. В.EgshatyanL. V.

Егшатян Лилит Ваниковна, к.м.н., врач-эндокринолог, ассистент кафедры эндокринологии и диабетологии лечебного факультета; старший научный сотрудник отдела эндокринологии; старший научный сотрудник отделения патологии паращитовидных желез 

127473, Москва, ул. Делегатская, д. 20, стр. 1;111123, Москва, шоссе Энтузиастов, д. 86; 117036, Москва, ул. Дмитрия Ульянова, д. 11 

Lilit V. Egshatyan, Cand. Sci. (Med.), Endocrinologist, Assistant of the Department of Endocrinology and Diabetology of the Medical Faculty; Senior Researcher of Department of Endocrinology; Senior Researcher of Department of Pathology of the Parathyroid Glands

20, Bldg. 1, Delegatskaya St., Moscow, 127473;86, Entuziastov Shosse, Moscow, 111123;11, Dmitry Ulyanov St., Moscow, 117036

lilit.egshatyan@yandex.ruМосковский государственный медико-стоматологический университет имени А.И. Евдокимова; Московский клинический научный центр имени А.С. ЛогиноваРоссияYevdokimov Moscow State University of Medicine and Dentistry; Loginov Moscow Clinical Scientific CenterRussian FederationМосковский государственный медико-стоматологический университет имени А.И. Евдокимова; Московский клинический научный центр имени А.С. Логинова; Национальный медицинский исследовательский центр эндокринологииРоссияYevdokimov Moscow State University of Medicine and Dentistry; Loginov Moscow Clinical Scientific Center; Endocrinology Research CentreRussian Federation20232612202206264273Copyright © Мкртумян А.М., Егшатян Л.В., 20232023Мкртумян А.М., Егшатян Л.В.Mkrtumyan A.M., Egshatyan L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7275

В  ряду пандемий хронических неинфекционных заболеваний особое место занимает сахарный диабет 2-го типа  (СД2), демонстрирующий стремительную распространенность. Во многих странаяяяяях СД2 является социально значимым заболеванием. По скромным данным, численность пациентов с СД2 в мире за последние 10 лет увеличилась более чем в два раза. Еще более тревожным является факт наличия более 250 млн людей с недиагностированным СД2 и более 300 млн с преддиабетом. Согласно неутешительным прогнозам Международной диабетической федерации, к  2045  г. СД будет страдать около 693 млн человек. Сложная и многогранная природа СД2 предполагает дальнейшее погружение в ее изучение и поиск лекарственных средств своевременного воздействия на патогенетические звенья его развития. Сердечно-сосудистые заболевания (ССЗ) являются основной причиной заболеваемости и смертности у пациентов с СД2, а сам диабет является значительным независимым фактором риска развития ишемической болезни сердца, инсульта и  смерти от  других сосудистых причин. В статье обсуждается актуальная проблема современного здравоохранения – снижение риска развития сердечнососудистых осложнений у пациентов с СД2 одним из представителей нового класса сахароснижающих препаратов (экзогенно вводимый агонист рецепторов глюкагоноподобного пептида 1  – арГПП-1) семаглутидом. Авторами рассматриваются основные результаты клинической программы SUSTAIN и  приоритетного назначения семаглутида в  качестве препарата первой линии пациентам с СД2 с очень высоким сердечно-сосудистым риском, обозначенного в новых европейских рекомендациях, с целью получения дополнительных преимуществ в отношении жизненного прогноза.

Type 2 diabetes mellitus (T2DM) dominates the chronic non-communicable disease pandemics by its exceptionally rapid expansion into communities all over the world. In many countries diabetes is a socially significant disease. According to the data over the past decade, the number of people with T2DM has more than doubled globally. Equally disturbing is the fact that there are more than 250 million people with undiagnosed T2DM and more than 300 million with prediabetes. For 2045, it was estimated by the International Diabetes Federation that 693 million people will have diabetes. T2DM is a disorder of complex nature that urges further dedicated studies and ingenuity in the search for novel therapeutic approaches and on the pathogenetic links of disease. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in people with T2DM, and diabetes itself confers a substantial independent risk of coronary heart disease, stroke, and death from other vascular causes. The article discusses an urgent challenge of modern healthcare – the role of new class of sugar-lowering drugs (exogenously administered glucagon-like peptide-1 receptor agonists (arGLP-1)) semaglutide in reducing the risk of developing cardiovascular complications. The authors paid attention to the main results of SUSTAIN clinical program and use as initial treatment for patients with T2DM with very high risk indicated in the new European guidelines with a view to get additional advantages in terms of life prognosis. 

сахарный диабет 2-го типасемаглутидагонисты рецепторов глюкагоноподобного пептида 1сердечно-сосудистые осложненияклиническая программа SUSTAINtype 2 diabetes mellitussemaglutideglucagon-like peptide-1 receptor agonistscardiovascular complicationsSUSTAIN clinical programReferencesДедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17.Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104–112. (In Russ.) https://doi.org/10.14341/DM2004116-17.Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759.Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus. 2021;24(3):204–221. (In Russ.) https://doi.org/10.14341/DM12759.Diabetes Control and Complications Trial Research Group, Nathan D.M., Genuth S., Lachin J., Cleary P., Crofford O., Davis M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. https://doi.org/10.1056/NEJM199309303291401.Diabetes Control and Complications Trial Research Group, Nathan D.M., Genuth S., Lachin J., Cleary P., Crofford O., Davis M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. https://doi.org/10.1056/NEJM199309303291401.Della Corte V., Tuttolomondo A., Pecoraro R., Di Raimondo D., Vassallo V., Pinto A. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016;22(30):4658–4668. https://doi.org/10.2174/1381612822666160510124801.Della Corte V., Tuttolomondo A., Pecoraro R., Di Raimondo D., Vassallo V., Pinto A. Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr Pharm Des. 2016;22(30):4658–4668. https://doi.org/10.2174/1381612822666160510124801.Giblett J.P., Axell R.G., White P.A., Clarke S.J., McCormick L., Read P.A. et al. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol. 2016;15:99. https://doi.org/10.1186/s12933-016-0416-3.Giblett J.P., Axell R.G., White P.A., Clarke S.J., McCormick L., Read P.A. et al. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol. 2016;15:99. https://doi.org/10.1186/s12933-016-0416-3.Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209-15. https://doi.org/10.1152/ajpendo.00237.2004.Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209-15. https://doi.org/10.1152/ajpendo.00237.2004.Aldiss P., Davies G., Woods R., Budge H., Sacks H.S., Symonds M.E. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–274. https://doi.org/10.1016/j.ijcard.2016.11.074.Aldiss P., Davies G., Woods R., Budge H., Sacks H.S., Symonds M.E. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–274. https://doi.org/10.1016/j.ijcard.2016.11.074.Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Pénicaud L. et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes. 2008;57(10):2577–2587. https://doi.org/10.2337/db08-0121.Cabou C., Campistron G., Marsollier N., Leloup C., Cruciani-Guglielmacci C., Pénicaud L. et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes. 2008;57(10):2577–2587. https://doi.org/10.2337/db08-0121.Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53:2181–2189. https://doi.org/10.2337/diabetes.53.9.2181.Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes. 2004;53:2181–2189. https://doi.org/10.2337/diabetes.53.9.2181.White J.R. A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2014;27(2):82–86. https://doi.org/10.2337/diaspect.27.2.82.White J.R. A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2014;27(2):82–86. https://doi.org/10.2337/diaspect.27.2.82.Gram D.X., Knudsen S.M., Nielsen F.S., Thygesen P., Reedtz-Runge S., Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726.Gram D.X., Knudsen S.M., Nielsen F.S., Thygesen P., Reedtz-Runge S., Kruse T. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726.Sorli C., Harashima S.I., Tsoukas G.M., Unger J., Karsbøl J.D., Hansen T., Bain S.C. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. https://doi.org/10.1016/S2213-8587(17)30013-X.Sorli C., Harashima S.I., Tsoukas G.M., Unger J., Karsbøl J.D., Hansen T., Bain S.C. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. https://doi.org/10.1016/S2213-8587(17)30013-X.Ahrén B., Masmiquel L., Kumar H., Sargin M., Karsbøl J.D., Jacobsen S.H., Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354. https://doi.org/10.1016/S2213-8587(17)30092-X.Ahrén B., Masmiquel L., Kumar H., Sargin M., Karsbøl J.D., Jacobsen S.H., Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–354. https://doi.org/10.1016/S2213-8587(17)30092-X.Ahmann A.J., Capehorn M., Charpentier G., Dotta F., Henkel E., Lingvay I. et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018;41(2):258–266. https://doi.org/10.2337/dc17-0417.Ahmann A.J., Capehorn M., Charpentier G., Dotta F., Henkel E., Lingvay I. et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018;41(2):258–266. https://doi.org/10.2337/dc17-0417.Aroda V.R., Bain S.C., Cariou B., Piletič M., Rose L., Axelsen M. et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as addon to metformin (with or without sulfonylureas) in insulinnaive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. https://doi.org/10.1016/S2213-8587(17)30085-2.Aroda V.R., Bain S.C., Cariou B., Piletič M., Rose L., Axelsen M. et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as addon to metformin (with or without sulfonylureas) in insulinnaive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. https://doi.org/10.1016/S2213-8587(17)30085-2.Rodbard H.W., Lingvay I., Reed J., de la Rosa R., Rose L., Sugimoto D. et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301. https://doi.org/10.1210/jc.2018-00070.Rodbard H.W., Lingvay I., Reed J., de la Rosa R., Rose L., Sugimoto D. et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301. https://doi.org/10.1210/jc.2018-00070.Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A. et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A. et al.; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.Pratley R.E., Aroda V.R., Lingvay I., Lüdemann J., Andreassen C., Navarria A., Viljoen A.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. https://doi.org/10.1016/S2213-8587(18)30024-X.Pratley R.E., Aroda V.R., Lingvay I., Lüdemann J., Andreassen C., Navarria A., Viljoen A.; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. https://doi.org/10.1016/S2213-8587(18)30024-X.Lingvay I., Catarig A.M., Frias J.P., Kumar H., Lausvig N.L., le Roux C.W. et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–844. https://doi.org/10.1016/S2213-8587(19)30311-0.Lingvay I., Catarig A.M., Frias J.P., Kumar H., Lausvig N.L., le Roux C.W. et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–844. https://doi.org/10.1016/S2213-8587(19)30311-0.Zinman B., Bhosekar V., Busch R., Holst I., Ludvik B., Thielke D. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9) : a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367. https://doi.org/10.1016/S2213-8587(19)30066-X.Zinman B., Bhosekar V., Busch R., Holst I., Ludvik B., Thielke D. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9) : a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367. https://doi.org/10.1016/S2213-8587(19)30066-X.Capehorn M.S., Catarig A.M., Furberg J.K., Janez A., Price H.C., Tadayon S. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109. https://doi.org/10.1016/j.diabet.2019.101117.Capehorn M.S., Catarig A.M., Furberg J.K., Janez A., Price H.C., Tadayon S. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–109. https://doi.org/10.1016/j.diabet.2019.101117.Kaku K., Yamada Y., Watada H., Abiko A., Nishida T., Zacho J., Kiyosue A. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obes Metab. 2018;20(5):1202–1212. https://doi.org/10.1111/dom.13218.Kaku K., Yamada Y., Watada H., Abiko A., Nishida T., Zacho J., Kiyosue A. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes Obes Metab. 2018;20(5):1202–1212. https://doi.org/10.1111/dom.13218.Chun J.H., Butts A. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. JAAPA. 2020;33(8):3–18. https://doi.org/10.1097/01. JAA.0000669456.13763.bd.Chun J.H., Butts A. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. JAAPA. 2020;33(8):3–18. https://doi.org/10.1097/01. JAA.0000669456.13763.bd.Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. https://doi.org/10.1016/j.jacc.2019.03.010.Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. https://doi.org/10.1016/j.jacc.2019.03.010.Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M. et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868.Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M. et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868.Pantalone K.M., Misra-Hebert A.D., Hobbs T.M., Ji X., Kong S.X., Milinovich A. et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54. https://doi.org/10.1186/s12933-018-0699-7.Pantalone K.M., Misra-Hebert A.D., Hobbs T.M., Ji X., Kong S.X., Milinovich A. et al. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54. https://doi.org/10.1186/s12933-018-0699-7.Шестакова М.В., Шамхалова М.Ш., Галстян Г.Р., Руяткина Л.А., Суплотова Л.А. Пероральный семаглутид – новая инновационная опция в терапии сахарного диабета 2 типа. Сахарный диабет. 2021;24(3):273–281. https://doi.org/10.14341/DM12790.Shestakova M.V., Shamkhalova M.S., Galstyan G.R., Ruyatkina L.A., Suplotova L.A. Oral semaglutide: the innovation in type 2 diabetes management. Diabetes Mellitus. 2021;24(3):273–281. (In Russ.) https://doi.org/10.14341/DM12790.Rakipovski G., Rolin B., Nøhr J., Klewe I., Frederiksen K.S., Augustin R. et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844–857. https://doi.org/10.1016/j.jacbts.2018.09.004.Rakipovski G., Rolin B., Nøhr J., Klewe I., Frederiksen K.S., Augustin R. et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844–857. https://doi.org/10.1016/j.jacbts.2018.09.004.Pratley R.E., Crowley M.J., Gislum M., Hertz C.L., Jensen T.B., Khunti K. et al. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021;12(4):1099–1116. https://doi.org/10.1007/s13300-020-00994-9.Pratley R.E., Crowley M.J., Gislum M., Hertz C.L., Jensen T.B., Khunti K. et al. Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021;12(4):1099–1116. https://doi.org/10.1007/s13300-020-00994-9.Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.Introduction: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl. 1):1–2. https://doi.org/10.2337/dc19-SINT01.Introduction: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl. 1):1–2. https://doi.org/10.2337/dc19-SINT01.American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):98–110. https://doi.org/10.2337/dc20-S009.American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):98–110. https://doi.org/10.2337/dc20-S009.Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 10-й выпуск. Сахарный диабет. 2021;24(Suppl. 1):1–148. https://doi.org/10.14341/DM12802.Dedov I.I., Shestakova M.V., Mayorov A.Yu. (eds.). Standards of specialized diabetes care. 10 th ed. Diabetes Mellitus. 2021;24(Suppl. 1):1–148. (In Russ.) https://doi.org/10.14341/DM12802.

The authors declare that there are no conflicts of interest present.